QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lake-street-maintains-buy-on-clearpoint-neuro-raises-price-target-to-15

Lake Street analyst Frank Takkinen maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $11 ...

 clearpoint-neuro-q2-2024-gaap-eps-016-beats-020-estimate-sales-7858m-beat-7330m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0....

 aspen-neuroscience-uses-mri-guided-clearpoint-navigation-system-for-patients-enrolled-in-aspiro-phase-12a-clinical-trial-for-transplantation-of-dopaminergic-neuron-precursor-cells-in-patients-with-parkinsons-disease

Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System

 clearpoint-neuro-q1-2024-gaap-eps-016-beats-019-estimate-sales-7639m-beat-6994m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0....

 clearpoint-neuro-congratulates-its-partner-aviadobio-on-first-patient-treated-in-its-aspire-ftd-clinical-trial-evaluating-avb-101-for-frontotemporal-dementia-with-grn-mutations

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-congratulates-its-partner-ptc-therapeutics-on-completion-of-biologics-license-application-submission-to-fda-for-upstaza-as-a-treatment-for-aadc-deficiency

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 stifel-reiterates-buy-on-clearpoint-neuro-raises-price-target-to-9

Stifel analyst Mathew Blackman reiterates ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $8 to $9.

 clearpoint-neuro-q4-2023-gaap-eps-019-beats-020-estimate-sales-6810m-beat-6533m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0....

 earnings-scheduled-for-march-12-2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

 journal-of-neurosurgery-publication-demonstrates-advantages-of-clearpoint-prism-neuro-laser-therapy-system

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION